Novartis’ Cosentyx Receives Positive CHMP Opinion for Polymyalgia Rheumatica in Europe Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization for Cosentyx® (secukinumab)…
Merck Launches “Your Hive of Whole Health” Program to Support Whole-Person Well-Being for People Living With HIV Merck (NYSE: MRK), known as MSD outside the United States and Canada, has launched Your Hive of Whole Health, a new multi-year educational…
Sensorion to Host SENS-601 Program Day on GJB2-Related Hearing Loss Gene Therapy Sensorion (FR001401A9Z0 – ALSEN), a clinical-stage biotechnology company focused on developing novel therapies designed to restore, treat, and prevent hearing loss disorders, has announced registration and connection details…
Takeda Awards $22.2 Million to Four Global CSR Partners to Strengthen Climate-Resilient Health Systems Takeda (TSE: 4502/NYSE: TAK) has announced a total commitment of $22.2 million to four new Global Corporate Social Responsibility (CSR) partners as part of its continuing…
AptarGroup and MGH’s Alice Stanton Launch Research Collaboration to Advance Nose-to-Brain Drug Delivery AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, dosing and protection technologies and consumer product dispensing, has announced a new research collaboration with Alice Stanton,…
AESARA Appoints Denise Sánchez as Vice President of Regulatory Counsel & Compliance Strategies AESARA, a leading Value & Access agency, has announced the appointment of Denise Sánchez, JD, MS, MA, as Vice President, Regulatory Counsel & Compliance Strategies. Sánchez brings…
Retension Pharmaceuticals Forms Scientific Advisory Board to Support RTN-001 Phase 2b Hypertension Development Retension Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing medicines for hypertension and other cardiovascular diseases, has announced the formation of a Scientific Advisory Board (SAB)…
Novo Nordisk Reports Positive Phase 3 STEP Young Results for Semaglutide in Children With Obesity Novo Nordisk has announced the first results from the STEP Young Phase 3 trial evaluating once-weekly semaglutide in children aged 6 to under 12 years…
Exegenesis Bio and Modalis Partner to Advance MDL-201 Gene Therapy for Duchenne Muscular Dystrophy Exegenesis Bio and Modalis Therapeutics Corporation (TOKYO: 4883) have entered into a research collaboration and license agreement aimed at advancing MDL-201, an investigational therapeutic candidate being…
Kallisio Expands Patient Access Program for Stentra in Head and Neck Cancer Radiation Therapy Kallisio has announced an expanded patient access program designed to help people preparing for radiation therapy for head and neck cancer obtain Stentra, a custom-fit, 3D-printed…
InduPro Publishes Nature Study Defining New Proximity-Based Targets for Cancer Therapeutics InduPro, Inc., a biotechnology company developing novel therapeutics for cancer and autoimmune diseases through protein proximity biology, has announced the publication of new research in the peer-reviewed scientific journal…
Flatiron Health and NCCN Renew Collaboration to Expand Real-World Evidence Research in Oncology Flatiron Health, a leading healthtech company focused on improving cancer care and advancing oncology research through real-world data (RWD), has announced the renewal of its long-standing collaboration…